RecruitingNCT06075693
Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy
Studying Steinert myotonic dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Massachusetts General Hospital
- Principal Investigator
- Thurman M Wheeler, MDMassachusetts General Hospital
- Enrollment
- 88 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2028
Study locations (1)
- Massachusetts General Hospital, Boston, Massachusetts, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06075693 on ClinicalTrials.govOther trials for Steinert myotonic dystrophy
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT06926621A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type IVertex Pharmaceuticals Incorporated
- RECRUITINGPHASE1, PHASE2NCT06185764A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)Vertex Pharmaceuticals Incorporated
- RECRUITINGPHASE1, PHASE2NCT05481879Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1Dyne Therapeutics
- ENROLLING BY INVITATIONNCT06979024A Registered Observational Cohort Study of Myotonic Dystrophy Type 1First Affiliated Hospital of Fujian Medical University